

### **Claim Amendments**

This listing of claims replaces all previous versions and listings of claims.

### **Listing of Claims**

1-34. (Canceled)

35. (Currently Amended) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a GLP-1 peptide comprising the amino acid sequence of {SEQ ID NO. 3} to treat hypertension.

36. (Previously Presented) The method of claim 35, wherein GLP-1 is administered peripherally.

37. (Previously Presented) The method of claim 35, wherein GLP-1 is administered subcutaneously.

38. (Previously Presented) The method of claim 35, wherein GLP-1 is administered intravenously.

39. (Previously Presented) The method of claim 35, wherein the therapeutically effective amount is from 1  $\mu$ g to 5 mg per dose.

40. (Previously Presented) The method of claim 35, wherein the administration is oral, buccal, pulmonary, nasal, intraocular, rectal, or transdermal.

41. (Currently Amended) A method for treating hypertension in an individual in need thereof comprising peripherally administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising a GLP-1 peptide comprising the amino acid sequence of {SEQ ID NO. 3} and a pharmaceutically acceptable carrier to treat hypertension.

42. (Previously Presented) The method of claim 40, wherein the pharmaceutical composition is a slow release composition.

43. (Previously Presented) The method of claim 41, wherein the peripheral administration is subcutaneous.

44. (Previously Presented) The method of claim 41, wherein the peripheral administration is intravenous.

45. (Previously Presented) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a peptide having at least 95% sequence identity to a GLP-1 peptide comprising the amino acid sequence of (SEQ ID NO. 3) to treat hypertension.

46. (Previously Presented) The method of claim 46, wherein GLP-1 is administered peripherally.

47. (Previously Presented) The method of claim 46, wherein GLP-1 is administered subcutaneously.

48. (Previously Presented) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a peptide having at least 90% sequence identity to a GLP-1 peptide comprising the amino acid sequence of (SEQ ID NO. 3) to treat hypertension.

49. (Previously Presented) The method of claim 46, wherein GLP-1 is administered peripherally.

50. (Previously Presented) The method of claim 46, wherein GLP-1 is administered subcutaneously.

51. (Canceled )

52. (Canceled)

53. (Canceled)